Mohamed Zayed, MD
Vascular Surgery · Saint Louis, MONPI 1851525190
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 60.9% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $14,291, 4.6 times the $3,130 reported in 2019.
Across 116 payments — averaging $255.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$18K
- Cardiovascular Systems Inc.$4K
- Endologix LLC$2K
- Amgen$1K
- Angiodynamics, Inc.$1K
- Silk Road Medical, Inc.$864
- plus $2K from 11 others
Across 15 payments — averaging $4365.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acera Surgical, Inc.$34K
- Veryan Medical Incorporated$32K
What the payments were for
- Consulting fees$3,69412%
- Speaking & faculty fees$11,97340%
- Travel & lodging$8,72529%
- Food & beverage$5,26518%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 56 | $18,053 |
| Cardiovascular Systems Inc. | 21 | $4,479 |
| Endologix LLC | 1 | $1,800 |
| Amgen | 1 | $1,494 |
| Angiodynamics, Inc. | 7 | $1,137 |
| Silk Road Medical, Inc. | 6 | $864 |
| Inari Medical, Inc. | 3 | $574 |
| W. L. Gore & Associates, Inc. | 5 | $296 |
| Cook Medical LLC | 4 | $251 |
| Boston Scientific | 2 | $207 |
| Acera Surgical, Inc. | 3 | $194 |
| Abbott | 2 | $157 |
| Johnson & Johnson | 1 | $63 |
| Shockwave Medical, Inc | 1 | $31 |
| Bolton Medical Inc | 1 | $22 |
| Organogenesis Inc. | 1 | $20 |
| Smith+Nephew | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENDURANT IIS$14,410
- Diamondback Peripheral$2,160
- Peripheral Orbital Atherectomy System$1,902
- Ovation$1,800
- TurboHawk$1,608
- ENROUTE Transcarotid Neuroprotection System$994
- Abre$586
- ENROUTE Transcarotid Stent System$558
- ENHANCE Transcarotid Peripheral Access Kit$558
- ENROUTE 0.014 Guidewire$558
- AlphaVac$483
- Auryon Laser System 100-120 Vac$458
- FlowTriever$394
- ClotTriever$394
- Valiant Captivia$235
- GORE VIABAHN VBX Balloon Expandable Endo$230
- ENROUTE Transcarotid Stent$218
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$218
- GENERAL VASCULAR INTERVENTION$168
- Restrata Wound Matrix$167
How this compares
$29,657 in reported general payments places this provider in the 80th percentile of 92 vascular surgery providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $28,094 |
| XareltoRivaroxaban | 32 | $22,803 |
| ClopidogrelClopidogrel Bisulfate | 104 | $765 |
| Cilostazol | 35 | $444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $63 | $22,80332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 vascular surgery providers in Missouri.
Other vascular surgery in Saint Louis
- Jeffrey JimSaint Louis$1.2M
- Brian PetersonSaint Louis$216K
- Luis SanchezSaint Louis$178K
- Catherine WittgenSaint Louis$139K
- John OhmanSaint Louis$113K
- Patrick GeraghtySaint Louis$65K
- Nathan DrozSaint Louis$38K
- Vipul KhetarpaulSaint Louis$23K
- Zachary WankenSaint Louis$18K
- Matthew SmedsSaint Louis$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.